Why NAD+ Causes Flushing (and Why Injection Speed Fixes It)

Ask anyone who has run an NAD+ protocol what the hardest part is, and the answer is rarely the dose — it's the flushing, chest tightness, and nausea that show up when it's administered too quickly. That reaction is well documented enough in clinic-administered IV contexts that infusion rate, not just total dose, is treated as a primary safety variable — and the same logic carries over directly to self-administered subcutaneous use.

The leading explanation centers on NAD+ metabolism itself. As NAD+ is processed, one of its breakdown products increases activity at adenosine receptors and triggers histamine-adjacent vasodilation — a rapid widening of blood vessels. Flood the bloodstream with a large amount of NAD+ at once, and that vasodilatory signal spikes all at once too, which is what produces the sudden facial flushing, a feeling of chest pressure, and sometimes lightheadedness.

Slow the same total dose down — administered over several minutes instead of seconds, or split into smaller sequential sub-doses — and the metabolic byproduct is produced more gradually, giving the vasodilatory response time to stay manageable instead of spiking. This is the actual mechanism behind the near-universal community advice to "go slow," and it's why the fix for a bad reaction is almost never a lower total dose — it's a slower one.

It's also why NAD+ is one of the few compounds on this site where the administration notes matter as much as the dosing schedule itself. Two people running the identical weekly total can have completely different experiences depending entirely on how each injection was paced.